- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Paul N. Van de Water Explains the Challenges with Controlling Healthcare Costs and Spending
Paul N. Van de Water, senior fellow, Center on Budget and Policy Priorities, suggests that controlling healthcare costs and spending is a complicated process - one in which no right answer exists.
Paul N. Van de Water, senior fellow, Center on Budget and Policy Priorities, suggests that controlling healthcare costs and spending is a complicated process — one in which no right answer exists. He says that healthcare stakeholders will need to try a number of approaches, with each approach carrying a different trade-off.
“Controlling healthcare costs means lower growth of income for some healthcare providers — it could mean the beneficiaries have to pay more, it could mean the beneficiaries have a more limited choice of providers,” Mr Van de Water says. “We can’t expect to control costs in a painless fashion.”
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
